CBLI

Cytocom, Inc. (CBLI) | Rumor.io

Cytocom

CBLI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CBLI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% -0.03	0% new	0% +0

Aug 16

Cytocom, Inc. (CBLI) reported a GAAP EPS of -$0.04 for Q2 2021.
The company's Q2 2021 financial results conference call is available for replay via webcast.
Cleveland BioLabs, Inc. filed SEC Form 8-K with results of operations and financial condition for Q2 2021.

Generated by AI

Sentiment

Of the messages about CBLI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0%	57.14% -18.46
Bearish	100%	100%	100%	42.86% +18.46

Bullish· Oct 20

$CBLI has shown a strong reversal, with a potential for significant gains, as seen in a morning trade from $3.83 to $4.83.
The asset has been identified as a "Nice winning trade" and a "BANGER" with a significant price increase, indicating strong market interest and potential for further growth.
Cytocom, the company behind $CBLI, has been recognized as a "promising biotech company" with a potential takeover/merger in the works, which could lead to a significant stock price jump to $10.

Bearish· Apr 21

$CBLI's price is likely to drop, as it is setting up for a short with a chart pattern.
The company has a limited amount of cash left, with only 12 months of cash left to burn, which may lead to financial difficulties.
The stock's volume is anemic and dropping, indicating a lack of investor interest and potentially a decline in the stock's value.

Generated by AI

Topics

Of the messages about CBLI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	77.78%
Controversies	—	—	—	11.11%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	11.11%

Apr 14

Genome Protection, a subsidiary of Cytocom, Inc. ($CBLI), has announced the publication of a next-generation deimmunized TLR5 agonist, GP532.
This announcement marks a significant development in the field of immunology and could have potential implications for the treatment of various diseases.
The publication of GP532 is a key milestone for Genome Protection and may have a positive impact on the company's stock price.

Generated by AI

Community

Of the messages about CBLI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	0.13%	0.13%
Newcomers	0%	0%	99.87%	99.87%

Regulars· Jul 7

The investor call and live webcast on Wednesday, July 7 at 8:30 a.m. has been announced, with some hoping for a similar run-up as seen with $ORPH's 1,000% jump.
With a $98M market capitalization, Cleveland BioLabs, Inc. is progressing through 6 clinical trials across multiple indications, including oncology and autoimmune diseases, with $200B market opportunities.
Historically, when CBLI drops 21.3% during a trading day, it has recovered by the same day's market close 73% of the time, suggesting a potential bounce.

Newcomers· Apr 14

Newcomers to Cytocom, Inc. (CBLI) are discussing its potential as a stock, with some expressing interest in the company.
Cytocom, Inc. (CBLI) is being compared to other companies, such as Fisker (TSLA) and Hero Technologies (HENC), which are exploring marketing opportunities.
The company's genome protection technology, GP532, is being highlighted as a key area of interest, with some noting its potential as a significant development for the company.

Generated by AI

Also Discussed

Investors talking about CBLI also mention

#	Name	Attention
1	GSS - Golden Star Resources Ltd.	——
2	XMax Inc.NVFY	0%0
3	VBLT - Vascular Biogenics Ltd.	——
4	AB Corporate Bond ETFEYEG	0%0
5	Nanoviricides Inc.NNVC	0%0
6	CATB - Catabasis Pharmaceuticals, Inc.	——
7	REPH - Recro Pharma, Inc.	——
8	CTIC - CTI BioPharma Corp.	——
9	Proficient Auto Logistics, Inc.PAL	0%0
10	NXTD - Nxt-ID, Inc.	——

Cytocom, Inc.

Location

Social

What share of all stock conversation is about CBLI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% -0.03	0% new	0% +0

Aug 16

Cytocom, Inc. (CBLI) reported a GAAP EPS of -$0.04 for Q2 2021.
The company's Q2 2021 financial results conference call is available for replay via webcast.
Cleveland BioLabs, Inc. filed SEC Form 8-K with results of operations and financial condition for Q2 2021.

Generated by AI

Sentiment

Of the messages about CBLI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0%	57.14% -18.46
Bearish	100%	100%	100%	42.86% +18.46

Bullish· Oct 20

$CBLI has shown a strong reversal, with a potential for significant gains, as seen in a morning trade from $3.83 to $4.83.
The asset has been identified as a "Nice winning trade" and a "BANGER" with a significant price increase, indicating strong market interest and potential for further growth.
Cytocom, the company behind $CBLI, has been recognized as a "promising biotech company" with a potential takeover/merger in the works, which could lead to a significant stock price jump to $10.

Bearish· Apr 21

$CBLI's price is likely to drop, as it is setting up for a short with a chart pattern.
The company has a limited amount of cash left, with only 12 months of cash left to burn, which may lead to financial difficulties.
The stock's volume is anemic and dropping, indicating a lack of investor interest and potentially a decline in the stock's value.

Generated by AI

Topics

Of the messages about CBLI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	77.78%
Controversies	—	—	—	11.11%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	11.11%

Apr 14

Genome Protection, a subsidiary of Cytocom, Inc. ($CBLI), has announced the publication of a next-generation deimmunized TLR5 agonist, GP532.
This announcement marks a significant development in the field of immunology and could have potential implications for the treatment of various diseases.
The publication of GP532 is a key milestone for Genome Protection and may have a positive impact on the company's stock price.

Generated by AI

Community

Of the messages about CBLI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	0.13%	0.13%
Newcomers	0%	0%	99.87%	99.87%

Regulars· Jul 7

The investor call and live webcast on Wednesday, July 7 at 8:30 a.m. has been announced, with some hoping for a similar run-up as seen with $ORPH's 1,000% jump.
With a $98M market capitalization, Cleveland BioLabs, Inc. is progressing through 6 clinical trials across multiple indications, including oncology and autoimmune diseases, with $200B market opportunities.
Historically, when CBLI drops 21.3% during a trading day, it has recovered by the same day's market close 73% of the time, suggesting a potential bounce.

Newcomers· Apr 14

Newcomers to Cytocom, Inc. (CBLI) are discussing its potential as a stock, with some expressing interest in the company.
Cytocom, Inc. (CBLI) is being compared to other companies, such as Fisker (TSLA) and Hero Technologies (HENC), which are exploring marketing opportunities.
The company's genome protection technology, GP532, is being highlighted as a key area of interest, with some noting its potential as a significant development for the company.

Generated by AI

Cytocom

Social

Aug 16

Sentiment

Bullish· Oct 20

Bearish· Apr 21

Topics

Apr 14

Community

Regulars· Jul 7

Newcomers· Apr 14

Also Discussed

Cytocom, Inc.

Company Information

Location

Also Discussed

Social

Aug 16

Sentiment

Bullish· Oct 20

Bearish· Apr 21

Topics

Apr 14

Community

Regulars· Jul 7

Newcomers· Apr 14